著者
Sho YOSHIMOTO Daiki KATO Satoshi KAMOTO Kie YAMAMOTO Masaya TSUBOI Masahiro SHINADA Namiko IKEDA Yuiko TANAKA Ryohei YOSHITAKE Shotaro ETO Kohei SAEKI James CHAMBERS Yuko HASHIMOTO Kazuyuki UCHIDA Ryohei NISHIMURA Takayuki NAKAGAWA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.20-0026, (Released:2020-04-03)
被引用文献数
6

Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic therapies for dogs with late-stage cPLC. HER2-targeted therapy could be an option for cPLC, but HER2 expression in cPLC remains unknown. We evaluated HER2 expression in cPLC. Immunohistochemical analysis revealed that 3 samples (19%) scored 3+; 8 (50%), 2+; 5 (31%); and 1+ and 0 (0%), 0. Of the cPLC tissues, 69% were HER2 positive (scored ≥2+). These data would lead to further evaluation of the role of HER2 in cPLC as a mechanism of malignancy and therapeutic target.
著者
Sho YOSHIMOTO Daiki KATO Satoshi KAMOTO Kie YAMAMOTO Masaya TSUBOI Masahiro SHINADA Namiko IKEDA Yuiko TANAKA Ryohei YOSHITAKE Shotaro ETO Kohei SAEKI James Kenn CHAMBERS Ryohei KINOSHITA Kazuyuki UCHIDA Ryohei NISHIMURA Takayuki NAKAGAWA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.19-0019, (Released:2019-05-29)
被引用文献数
12

Canine anal sac gland carcinoma (ASGC) frequently occurs in the apocrine glands of the canine anal sac and shows aggressive biological behavior. The expression of human epidermal growth factor receptor 2 (HER2) has been reported in various human and canine tumors. HER2 is a promising therapeutic target of these tumors, and HER2-targeted drugs, such as trastuzumab and lapatinib, have improved the outcome of these patients. In this study, HER2 expression in ASGC was evaluated to investigate its potential as a therapeutic target for canine ASGC. HER2 mRNA expression in surgically resected ASGC tissues was significantly higher than that in normal anal sac tissue. To evaluate the expression of HER2 protein, paraffin-embedded ASGC tissues were immunohistochemically evaluated. Strong and broad staining of HER2 was detected in ASGC tissues, while HER2 was weakly to moderately stained in normal anal sac apocrine glands and squamous epithelia. The degree of HER2 expression in ASGC tissues was scored based on its intensity and positivity (score: 0–3+). Scoring of HER2 expression revealed 6 samples (24%) scored 3+, 14 (56%) scored 2+, and 5 (20%) scored 1+, with no samples scoring 0. In all, 80% of canine ASGC tissues were positive for HER2 (scored ≥2+). Furthermore, putative HER2-overexpressed cells in ASGC were detected with trastuzumab by flow cytometry. These preliminary data may lead to further evaluation of the role of HER2 in canine ASGC as a mechanism of malignancy and as a therapeutic target for HER2-targeted therapy.
著者
Namiko IKEDA Daiki KATO Masaya TSUBOI Ryohei YOSHITAKE Shotaro ETO Sho YOSHIMOTO Masahiro SHINADA Satoshi KAMOTO Yuko HASHIMOTO Yousuke TAKAHASHI James CHAMBERS Kazuyuki UCHIDA Ryohei NISHIMURA Takayuki NAKAGAWA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
vol.83, no.12, pp.1885-1890, 2021 (Released:2021-12-02)
参考文献数
27
被引用文献数
1

Cancer immunotherapy is a novel cancer treatment for canine tumors. Indoleamine 2,3-dioxygenase 1 (IDO1) is overexpressed in some human tumors and inhibits antitumor immunity. In this study, we comprehensively evaluated expression pattern of IDO1 and the nature of IDO1-expressing cells in canine normal and tumor tissues. In normal tissue samples, IDO1 expression was detected only in the lymph nodes, spleen, tonsil tissues, and colon tissues. In contrast, IDO1-positive tumor cells were observed in several tumor tissue types. This is the first study to evaluate IDO1 expression in canine normal and tumor tissues, and the results suggest that IDO1 is a promising target for novel cancer immunotherapy in dogs with tumors.
著者
Satoshi KAMOTO Masahiro SHINADA Daiki KATO Masaya TSUBOI Sho YOSHIMOTO Ryohei YOSHITAKE Shotaro ETO Namiko IKEDA Yosuke TAKAHASHI Yuko HASHIMOTO James CHAMBERS Kazuyuki UCHIDA Shinji YAMADA Mika K. KANEKO Ryohei NISHIMURA Yukinari KATO Takayuki NAKAGAWA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
vol.83, no.11, pp.1795-1799, 2021 (Released:2021-11-24)
参考文献数
37
被引用文献数
2

Podoplanin is expressed in various human tumors where it promotes tumor progression, epithelial-mesenchymal transition, and distant metastasis. Podoplanin is also expressed in cancer-associated fibroblasts and induces tumor malignancy. The objective of this study was to evaluate podoplanin expression in various types of feline tumor tissues. Immunohistochemical analysis revealed that podoplanin was expressed in cells of 13/15 (87%) squamous cell carcinomas and 5/19 (26%) fibrosarcomas. Moreover, cancer-associated fibroblasts expressed podoplanin in most tumor types, including 18/21 (86%) mammary adenocarcinoma tissues. Our findings demonstrate that various types of feline tumor tissues expressed podoplanin, indicating the importance of the comparative aspects of podoplanin expression, which may be used as a novel research model for podoplanin biology.
著者
Namiko IKEDA Daiki KATO Masaya TSUBOI Ryohei YOSHITAKE Shotaro ETO Sho YOSHIMOTO Masahiro SHINADA Satoshi KAMOTO Yuko HASHIMOTO Yousuke TAKAHASHI James CHAMBERS Kazuyuki UCHIDA Ryohei NISHIMURA Takayuki NAKAGAWA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.21-0217, (Released:2021-10-22)
被引用文献数
1

Cancer immunotherapy is a novel cancer treatment for canine tumors. Indoleamine 2,3-dioxygenase 1 (IDO1) is overexpressed in some human tumors and inhibits antitumor immunity. In this study, we comprehensively evaluated expression pattern of IDO1 and the nature of IDO1-expressing cells in canine normal and tumor tissues. In normal tissue samples, IDO1 expression was detected only in the lymph nodes, spleen, tonsil tissues, and colon tissues. In contrast, IDO1-positive tumor cells were observed in several tumor tissue types. This is the first study to evaluate IDO1 expression in canine normal and tumor tissues, and the results suggest that IDO1 is a promising target for novel cancer immunotherapy in dogs with tumors.
著者
Satoshi KAMOTO Masahiro SHINADA Daiki KATO Masaya TSUBOI Sho YOSHIMOTO Ryohei YOSHITAKE Shotaro ETO Namiko IKEDA Yosuke TAKAHASHI Yuko HASHIMOTO James CHAMBERS Kazuyuki UCHIDA Shinji YAMADA Mika K. KANEKO Ryohei NISHIMURA Yukinari KATO Takayuki NAKAGAWA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.20-0608, (Released:2021-10-18)
被引用文献数
2

Podoplanin is expressed in various human tumors where it promotes tumor progression, epithelial-mesenchymal transition, and distant metastasis. Podoplanin is also expressed in cancer-associated fibroblasts and induces tumor malignancy. The objective of this study was to evaluate podoplanin expression in various types of feline tumor tissues. Immunohistochemical analysis revealed that podoplanin was expressed in cells of 13/15 (87%) squamous cell carcinomas and 5/19 (26%) fibrosarcomas. Moreover, cancer-associated fibroblasts expressed podoplanin in most tumor types, including 18/21 (86%) mammary adenocarcinoma tissues. Our findings demonstrate that various types of feline tumor tissues expressed podoplanin, indicating the importance of the comparative aspects of podoplanin expression, which may be used as a novel research model for podoplanin biology.